LIS
CPRX

Legacy Investment Solutions’s Catalyst Pharmaceutical CPRX Stock Holding History

Legacy Investment Solutions’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$391 Buy
+18
New +$425 ﹤0.01% 674
2024
Q4 		$802 Buy
35
+17
+94% +$365 ﹤0.01% 616
2024
Q3 		$411 Buy
+18
New +$334 ﹤0.01% 625

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Legacy Investment Solutions's CPRX Position: Q2 2025 in Review

Legacy Investment Solutions opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2025: 18 shares worth $391. The stake represents ﹤0.01% of the portfolio and ranks #674 among its holdings. This is a return to the name: Legacy Investment Solutions previously reported a position in CPRX as recently as Q4 2024.

Legacy Investment Solutions first reported a position in CPRX in Q3 2024 and has held it in 3 quarters since. The position peaked at $802 in Q4 2024. 365 funds tracked by Wall St. Rank hold CPRX as of Q2 2025.

  • Legacy Investment Solutions held 18 shares of Catalyst Pharmaceutical worth $391 as of Q2 2025.
  • Catalyst Pharmaceutical was a new Legacy Investment Solutions position in Q2 2025.
  • Catalyst Pharmaceutical made up ﹤0.01% of Legacy Investment Solutions's portfolio in Q2 2025, its #674 holding.
  • Legacy Investment Solutions first reported a position in Catalyst Pharmaceutical in Q3 2024 and has held it in 3 quarters since.
  • Legacy Investment Solutions's Catalyst Pharmaceutical position peaked at $802 in Q4 2024.
  • 365 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2025.

Based on Legacy Investment Solutions's 13F filing for Q2 2025, filed 6 Aug 2025.